Forte Biosciences, Inc. (FBRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Forte Biosciences, Inc. on August 4, 2023, covering the event date of July 31, 2023. The filing addresses a change in the Company's independent registered public accountant.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Accountant Resignation: Mayer Hoffman McCann P.C. (MHM) informed the Company on July 31, 2023, that it would not stand for re-appointment for the fiscal year ending December 31, 2024.
- Transition Timeline: MHM will cease serving as the independent auditor upon the earliest of: (i) the appointment of a new firm, (ii) the filing of the 2023 Form 10-K, or (iii) April 1, 2024.
- Audit History: MHM's audit reports for the years ended December 31, 2021, and 2022, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
- Disagreements: There were no disagreements with MHM on accounting principles, practices, or auditing scope during the relevant periods.
- Reportable Events: No reportable events occurred other than management's conclusion in the 2022 Form 10-K regarding ineffective controls over the annual tax provision.
Guidance, Outlook, and Risks
The Audit Committee has initiated a process to select a new independent registered public accounting firm. The filing includes a letter from MHM (Exhibit 16.1) confirming their agreement with the disclosures made in this report. No financial guidance or forward-looking outlook is provided in this document.
Key Facts for Investor Verification
- Verify the timeline for the appointment of the new independent auditor.
- Review the Company's subsequent filings to confirm the selection of the new accounting firm.
- Monitor the status of the previously disclosed ineffective controls regarding the annual tax provision.
- Confirm that no undisclosed disagreements arose between management and MHM during the interim period.